Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Regula DP, Jr., Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 1988;318:214–219.
   PubMed Web of Science ®Google Scholar
• Pappa VI, Norton AJ, Gupta RK, et al. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol 1995;6:559–565.
   PubMed Web of Science ®Google Scholar
• Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997;15:3060–3066.
   PubMed Web of Science ®Google Scholar
• Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17:776–783.
   PubMed Web of Science ®Google Scholar
• Goel A, Fan W, Patel AA, et al. Nodular lymphocyte predominant Hodgkin lymphoma: biology, diagnosis and treatment. Clin Lymphoma Myeloma Leuk 2014;14:261–270.
   PubMed Web of Science ®Google Scholar
• Feugier P, Labouyrie E, Djeridane M, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 2004;104:2675–2681.
   PubMed Web of Science ®Google Scholar
• Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434–439.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 2011;118:4585–4590.
   PubMed Web of Science ®Google Scholar
• Gerber N, Atoria CL, Elkin EB, et al. Characteristics and outcomes of patients with lymphocyte-predominant Hodgkin lymphoma versus classical Hodgkin lymphoma: a population-based analysis. Int J Radiation Oncol Biol Phys 2014;90:S153–S154.
   Web of Science ®Google Scholar
• Hartmann S, Eichenauer DA, Plutschow A, et al. Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma – a matched pair analysis from the German Hodgkin Study Group (GHSG). Br J Haematol 2014;167:238–242.
   PubMed Web of Science ®Google Scholar
• Xing KH, Connors JM, Lai A, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood 2014;123:3567–3573.
   PubMed Web of Science ®Google Scholar
• Liao Z, Ha CS, Vlachaki MT, et al. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2001;50:971–977.
   PubMed Web of Science ®Google Scholar
• Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 2002;8: 377–383.
   PubMed Web of Science ®Google Scholar
• Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005;104:1221–1229.
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:589–597.
   PubMed Web of Science ®Google Scholar
• Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2014;32:912–918.
   PubMed Web of Science ®Google Scholar
• Solanki AA, LeMieux MH, Chiu BC, et al. Long-term outcomes in patients with early stage nodular lymphocyte-predominant Hodgkin's lymphoma treated with radiotherapy. PLoS One 2013; 8:e75336.
   PubMed Web of Science ®Google Scholar
• Xavier AC, Costa LJ. Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: implications for survival and second malignancies. Leuk Lymphoma 2014:1–16.
   Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424.
   PubMed Web of Science ®Google Scholar
• Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757–763.
   PubMed Web of Science ®Google Scholar
• Parikh RR, Yahalom J, Talcott JA, et al. Early-stage Hodgkin disease: the utilization of radiation therapy and its impact on overall survival. Int J Radiation Oncol Biol Phys 2014;90:S5.
   Web of Science ®Google Scholar
• Aviles A, Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. Clin Lab Haematol 1998;20:95–99.
   PubMedGoogle Scholar
• Herbst C, Rehan FA, Skoetz N, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011:CD007110.
   Google Scholar
• Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62–68.
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634–4642.
   PubMed Web of Science ®Google Scholar
• Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765–3771.
   PubMed Web of Science ®Google Scholar
• Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014;32:1188–1194.
   PubMed Web of Science ®Google Scholar
• Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma – clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010;21:2061–2068.
   PubMed Web of Science ®Google Scholar
• Ali S, Olszewski AJ. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study. Leuk Lymphoma 2014;55:1570–1577.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363–4365.
   PubMed Web of Science ®Google Scholar
• Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285–4289.
   PubMed Web of Science ®Google Scholar
• van Grotel M, Lam KH, de Man R, et al. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma 2006;47:1504–1510.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572–1582.
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431–3439.
   PubMed Web of Science ®Google Scholar
• Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117:1806–1816.
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Aznar MC, Vogelius IR, et al. Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2013;85:1057–1065.
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640–652.
   PubMed Web of Science ®Google Scholar
• Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916–1927.
   PubMed Web of Science ®Google Scholar
• Yahalom J. Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol 2006;24:544–548.
   PubMed Web of Science ®Google Scholar
• Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:3601–3608.
   PubMed Web of Science ®Google Scholar